Share this article on:

In-vitro phenotypic susceptibility of HIV-1 ’non-B’ integrase inhibitors naive clinical isolates to dolutegravir and raltegravir

Charpentier, Charlottea,b; Bertine, Mélaniea,b; Visseaux, Benoita,b; Leleu, Juliettea,b; Larrouy, Lucilea,b; Peytavin, Gillesa; Mourez, Thomasc; Collin, Gillesa,b; Brun-Vézinet, Françoisea,b; Plantier, Jean-C.b,c; Descamps, Dianea,b

doi: 10.1097/QAD.0000000000000016
Research Letters

In this study, we assessed phenotypic susceptibility to dolutegravir and raltegravir in a large variety of HIV-1 ‘non-B’ subtypes (n = 72) issued from integrase inhibitor-naive clinical isolates. All samples were susceptible to both dolutegravir and raltegravir with median IC50 values of 1.22 nmol/l and 1.53 nmol/l, respectively; similar to that observed for the B subtype. Thus, despite the high prevalence of polymorphic substitutions in integrase in ‘non-B’ clinical isolates, phenotypic susceptibility to dolutegravir remained unchanged.

aAssistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Université Paris 7, Paris

bHIV National Reference Center

cLaboratoire de Virologie, CHU Charles Nicolle, EA2656, université de Rouen, France.

Correspondence to Dr Charlotte Charpentier, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, 46 Rue Henri Huchard, 75018 Paris, France. Tel: +33 1 40 25 61 50; fax: +33 1 40 25 67 69; e-mail: charlotte.charpentier@bch.aphp.fr

Received 10 July, 2013

Revised 22 July, 2013

Accepted 22 July, 2013

Presented in part at the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, Canada, June 2013 [Abstract 83]

© 2013 Lippincott Williams & Wilkins, Inc.